natgillin/translations-raw huggingface dataset:
- The other ingredients are: carbomer, colloidal silicon dioxide (E551), hypromellose (E464), lactose monohydrate, magnesium stearate (E572), methacrylic acid copolymer, macrogol, povidone (E1201), red iron oxide (E172), talc (E533b) and titanium dioxide (E171). 
- Pomožne snovi so: karbomer, koloidni silicijev dioksid (E551), hipromeloza (E464), laktoza monohidrat, magnezijev stearat (E572), metakrilna kislina kopolimer, makrogol, povidon (E1201), rdeči železov oksid (E172), smukec (E553b) in titanov dioksid (E171).
- Common: 
- Pogosti:
Very common (more than 1 out of 10 patients): - headache - flushing - swelling, particularly of the ankles and legs 
Zelo pogosti (pri več kot 1 od 10 bolnikov): - glavobol - rdečica - otekanje, zlasti gležnjev in nog - vrtoglavica - nejasno zavedanje - občutek pritiska v glavi.
4.2 Posology and method of administration For oral administration. 
4.2 Odmerjanje in način uporabe
Nifedipine Pharmamatch tablets are supplied in blister packs of 28. 
Nifedipine Pharmamatch tablete so na voljo v pretisnih omotih po 28 tablet.
There are limited data showing that nifedipine is excreted into human breast milk at low levels. 
Omejeni podatki dokazujejo, da se nifedipin v majhnih količinah izloča v materino mleko in možnega vpliva na novorojenčka ni mogoče izključiti.
Nifedipine Pharmamatch 60 mg tablets are available as prolonged-release tablets in a calendar packaging of 28 tablets (2 blisters of 14 tablets). 
Nifedipine Pharmamatch 60 mg tablete so na voljo kot tablete s podaljšanim sproščanjem v koledarski ovojnini z 28 tabletami (2 pretisna omota s 14 tabletami).
Nifedipine Pharmamatch 30 mg tablets are available as prolonged-release tablets in a calendar packaging of 28 tablets (2 blisters of 14 tablets). 
Nifedipine Pharmamatch 30 mg tablete so na voljo kot tablete s podaljšanim sproščanjem v koledarski ovojnini z 28 tabletami (2 pretisna omota s 14 tabletami).
- if you have experienced a collapse which was caused by a heart problem (cardiogenic shock) - if you have a narrowed aorta (aortic stenosis). 
- Če ste se kdaj zgrudili zaradi težav s srcem (kardiogeni šok).
Nifedipine Pharmamatch retard 30 mg, prolonged-release tablets contain 30 mg nifedipine per tablet. 
Nifedipine Pharmamatch retard 30 mg, tablete s podaljšanim sproščanjem, vsebujejo 30 mg nifedipina na tableto.
- moisture in lungs (pulmonary oedema) - fainting (syncope) - heart block - peeling or flaking of skin (exfoliative dermatitis) - severe blistering of the skin and/or mucous membranes of the lips, eyes, mouth, nasal passages or genitals (signs of Steven-Johnson syndrome) - skin rashes (erythema multifome, pemphigus, fixed drug eruption, urticaria) - reduced production of red blood cells (aplastic anaemia) - increase in blood potassium levels (when used together with another medicine called propranolol) 
Steven-Johnsonovega sindroma) - izpuščaji na koži (multiformni eritem, pemfigus, fiksirane erupcije zaradi zdravil, urtikarija) - zmanjšana tvorba eritrocitov (aplastična anemija) - zvišanje ravni kalija v krvi (pri sočasnem jemanju nifedipina in zdravila propranolola)
Nifedipine Pharmamach retard tablets come in a calendar packing of 28 tablets (2 blisters of 14 tablets each). 
Nifedipine Pharmamatch retard tablete so na voljo v koledarski ovojnini z 28 tabletami (2 pretisna omota s po 14 tabletami).
Each tablet contains: 60 mg nifedipine 
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN Vsaka tableta vsebuje: 60 mg nifedipina
please tell your doctor or pharmacist. 
Če ste negotovi, obvestite svojega zdravnika ali farmacevta.
The possibility of an additive effect resulting in postural hypotension should be borne in mind when Nifedipine Pharmamatch retard is used in combination with other beta-blocking medicinal products and antihypertensive agents. 
Pri uporabi zdravila Nifedipine Pharmamatch retard v kombinaciji z drugimi zaviralci adrenergičnih receptorjev beta in zdravili za zdravljenje hipertenzije je treba upoštevati možnost aditivnega učinka, pri čemer bi se pojavila postularna hipotenzija.
It is not recommended to drink grapefruit juice when treated with Nifedipine Pharmamatch retard. 
V času zdravljenja z zdravilom Nifedipine Pharmamatch retard ni priporočljivo piti grenivkinega soka.
It should not be used for secondary prevention of myocardial infarction. 
Zdravila Nifedipine Pharmamatch retard ne smemo uporabljati za sekundarno preprečevanje miokardnega infarkta.
Nifedipine Pharmamatch retard 60 mg, prolonged-release tablets contain 60 mg nifedipine per tablet. 
Nifedipine Pharmamatch retard 60 mg, tablete s podaljšanim sproščanjem, vsebujejo 30 mg nifedipina na tableto.
Other interactions with nifedipine 
Medsebojno delovanje nifedipina z drugimi zdravili
Each tablet contains: 30 mg nifedipine 
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN Vsaka tableta vsebuje: 30 mg nifedipina
What Nifedipine Pharmamatch retard contains 
Kaj vsebuje zdravilo Nifedipine Pharmamatch retard
Nifedipine Pharmamatch retard 60 mg prolonged-release tablets Nifedipine 
Nifedipine Pharmamatch retard 60 mg tablete s podaljšanim sproščanjem nifedipin
Grapefruit juice inhibits the CYP3A4 system. 
Grenivkin sok zavira sistem CYP3A4.
In case of doubt, always contact your doctor or pharmacist. 
Če ste negotovi, se posvetujte z zdravnikom ali s farmacevtom.
Important information about some of the ingredients of Nifedipine Pharmamatch retard 
Pomembne informacije o nekaterih sestavinah zdravila Nifedipine Pharmamatch retard Zdravilo Nifedipine Pharmamatch retard vsebuje laktozo.
Nifedipine 
Zdravilo Nifedipine
Reproductive system and breast disorders: - Uncommon: 
Motnje reprodukcije in dojk: - Občasni:
Nifedipine Pharmamatch retard 30 mg prolonged-release tablets Nifedipine 
Nifedipine Pharmamatch retard 30 mg tablete s podaljšanim sproščanjem nifedipin
Each prolonged release tablet contains 60 mg nifedipine. 
KAKOVOSTNA IN KOLIČINSKA SESTAVA Vsaka tableta s podaljšanim sproščanjem vsebuje 60 mg nifedipina.
RVG 31823 - Nifedipine Pharmamatch retard 60 mg, prolonged-release tablets DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 29 November 2004 
ŠTEVILKA (ŠTEVILKE) DOVOLJENJA (DOVOLJENJ) ZA PROMET RVG 31823 - Nifedipine Pharmamatch retard 60 mg tablete s podaljšanim sproščanjem
Always take Nifedipine Pharmamatch retard exactly as your doctor has told you. 
Pri jemanju zdravila Nifedipine Pharmamatch retard natančno upoštevajte zdravnikova navodila.
Nifedipine is almost entirely metabolised (> 90%); approximately 70-80% is excreted in urine. 
Nifedipin se skoraj v celoti presnovi (> 90 %).
A reduction of the nifedipine dose can be considered. 
Po potrebi je treba znižati odmerek nifedipina.
It should not be used for acute attacks of angina. 
Zdravila Nifedipine Pharmamatch retard ne smemo uporabljati za akutne napade angine.
Eye disorders: - Uncommon: 
Očesne bolezni: - Občasni:
Stationsweg Oost 281D 
Stationsweg Oost 281D 3930 EB Woudenberg
- Very common: peripheral oedema, flushing (facial reddening). 
periferni edem, rdečica (na obrazu)
Each prolonged release tablet contains 30 mg nifedipine. 
KAKOVOSTNA IN KOLIČINSKA SESTAVA Vsaka tableta s podaljšanim sproščanjem vsebuje 30 mg nifedipina.
Nervous system disorders: - Uncommon: 
Bolezni živčevja: - Občasni:
Respiratory, thoracic and mediastinal disorders: - Very rare: 
pljučni edem, sinkopa, srčni blok Bolezni dihal, prsnega koša in mediastinalnega prostora: - Zelo redki:
Nifedipine Pharmamatch retard 60 mg prolonged-release tablets 
IME ZDRAVILA Nifedipine Pharmamatch retard 60 mg tablete s podaljšanim sproščanjem
colouring aid 
SEZNAM POMOŽNIH SNOVI
Nifedipine Pharmamatch retard 30 mg prolonged-release tablets 
IME ZDRAVILA Nifedipine Pharmamatch retard 30 mg tablete s podaljšanim sproščanjem
In patients with hepatic impairment careful monitoring is required and, in severe cases, a lowering of the dose may be necessary. 
Pri bolnikih z jetrno okvaro je potrebno skrbno spremljanje.
The recommended dose is 350 mg once every 3 weeks. 
Priporočeni odmerek je 350 mg enkrat vsake tri tedne.
However, the study involved a small number of patients and additional data are required. 
Ker pa je opravljena študija vključevala majhno število bolnikov, je potrebnih več podatkov.
Further information on Libtayo can be found on the Agency's website: www.ema.europa.eu/medicines/human/EPAR/libtayo. 
Nadaljnje informacije o zdravilu Libtayo so na voljo na spletni strani agencije: www.ema.europa.eu/medicines/human/EPAR/libtayo.
Treatment can continue for as long as the disease remains stable and the patient does not experience unacceptable side effects. 
Zdravljenje se nadaljuje tako dolgo, dokler bolezen ostaja stabilna in bolnik nima nesprejemljivih neželenih učinkov.
The European Medicines Agency therefore decided that Libtayo's benefits are greater than its risks and it can be authorised for use in the EU. 
Evropska agencija za zdravila je zato zaključila, da so koristi zdravila Libtayo večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
As for the medicine's safety, its side effects are manageable and similar to those seen in other cancer treatments of this type. 
Kar zadeva varnost zdravila, so njegovi neželeni učinki obvladljivi in podobni tistim, ki so bili opaženi pri drugih tovrstnih zdravilih za zdravljenja raka.
In a main study involving a total of 193 patients, the cancer shrank in around 39% of patients with metastatic disease who received 350 mg Libtayo every 3 weeks for around one year. 
V glavni študiji, v kateri je sodelovalo skupaj 193 bolnikov, se je rak skrčil pri približno 39 % bolnikov z metastatskim rakom, ki so približno eno leto prejemali 350 mg zdravila Libtayo vsake tri tedne.
What measures are being taken to ensure the safe and effective use of Libtayo? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Libtayo?
The company will also investigate whether the medicine works differently depending on the levels of PD-L1 produced by the cancer cells. 
Podjetje bo prav tako proučilo, ali je delovanje zdravila odvisno od ravni PD-L1, ki jo proizvajajo rakave celice.
Treatment with Libtayo must be started and supervised by a doctor experienced in treating cancer. 
Zdravljenje z zdravilom Libtayo mora začeti in nadzorovati zdravnik, ki ima izkušnje z zdravljenjem raka.
As for all medicines, data on the use of Libtayo are continuously monitored. 
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Libtayo stalno spremljajo.
Libtayo is given as an infusion (drip) into a vein lasting 30 minutes. 
Zdravilo Libtayo se daje kot (kapalna) infuzija v veno, ki traja 30 minut.
Among patients with locally advanced disease who received Libtayo every 2 weeks (at a dose of 3 mg/kg bodyweight) for around 2 years, 44% of patients showed shrinkage of their cancer. 
Med bolniki z lokalno napredovalim rakom, ki so približno dve leti prejemali zdravilo Libtayo (v odmerku 3 mg/kg telesne mase) vsaka dva tedna, se je rak skrčil pri 44 % bolnikov.
Libtayo has been given ‘conditional authorisation'. 
Zdravilo Libtayo je pridobilo „pogojno dovoljenje za promet“.
Side effects reported with Libtayo are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu Libtayo, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
Why is Libtayo authorised in the EU? 
Zakaj je bilo zdravilo Libtayo odobreno v EU?
Other information about Libtayo 
Druge informacije o zdravilu Libtayo
An overview of Libtayo and why it is authorised in the EU 
Pregled zdravila Libtayo in zakaj je odobreno v EU
What is Libtayo and what is it used for? 
Kaj je zdravilo Libtayo in za kaj se uporablja?
What benefits of Libtayo have been shown in studies? 
Kakšne koristi zdravila Libtayo so se pokazale v študijah?
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Libtayo have also been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Libtayo upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
For more information about using Libtayo, see the package leaflet or contact your doctor or pharmacist. 
Za več informacij glede uporabe zdravila Libtayo glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
Libtayo is associated with side effects related to the activity of the immune system, which can be serious, although most side effects go away with appropriate treatment or on stopping Libtayo. 
Zdravilo Libtayo je povezano z neželenimi učinki, ki prizadenejo delovanje imunskega sistema, pri čemer so ti lahko resni, čeprav jih večina izzveni tudi brez zdravljenja ali ob prenehanju dajanja zdravila Libtayo.
The most common immune-related effects (which may affect up to 1 in 10 people) were hypothyroidism (an underactive thyroid gland with tiredness, weight gain, and skin and hair changes), pneumonitis (inflammation in the lungs causing shortness of breath and cough), skin reactions, hyperthyroidism (an overactive thyroid gland which can cause hyperactivity, sweating, weight loss and thirst) and hepatitis (inflammation of the liver). 
Najpogostejši neželeni učinki, povezani z imunskim sistemom (ki se lahko pojavijo pri največ 1 osebi od 10), so hipotiroidizem (premalo aktivna ščitnica s spremljajočo utrujenostjo, povečanjem telesne mase, spremembami na koži in lasišču), pnevmonitis (vnetje v pljučih, ki povzroča zasoplost in kašelj), kožne reakcije, hipertiroidizem (prekomerno aktivna ščitnica, ki se odraža kot hiperaktivnost, potenje, izguba telesne mase in žeja) ter hepatitis (vnetje jeter).
Libtayo is a cancer medicine used on its own to treat adults with a type of skin cancer called cutaneous squamous cell carcinoma when the cancer is locally advanced (has spread nearby) or metastatic (has spread to other parts of the body). 
Libtayo je zdravilo za zdravljenje raka, ki se uporablja kot samostojno zdravilo pri odraslih z vrsto kožnega raka, imenovano ploščatocelični karcinom kože, ki je lokalno napredoval (se razširil v bližini žarišča) ali metastaziral (se razširil v druge dele telesa).
Severe reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis (life-threatening reactions with flu-like symptoms and painful rash affecting the skin, mouth, eyes and genitals) have been reported with Libtayo. 
Poročali so tudi o hudih reakcijah, vključno s Stevens-Johnsonovim sindromom in toksično epidermalno nekrolizo (življenjsko nevarne reakcije z gripi podobnimi simptomi in bolečimi izpuščaji, ki se pojavijo na koži, v ustih, na očeh in spolovilih).
The company that markets Libtayo will provide a guide and an alert card for patients with information on the signs and symptoms of immune-related side effects of the medicine, as well as instructions on contacting their doctor if they experience symptoms. 
Podjetje, ki trži zdravilo Libtayo, bo zagotovilo vodnik in opozorilno kartico za bolnike, ki bosta vsebovala informacije o znakih in simptomih neželenih učinkov zdravila, ki so povezani z imunskim sistemom, ter napotek, naj se v primeru pojava teh simptomov obrnejo na svojega zdravnika.
Since Libtayo has been given conditional authorisation, the company that markets Libtayo will provide data from an ongoing study on the effectiveness and safety of the medicine for cutaneous squamous cell carcinoma. 
Ker bilo za zdravilo Libtayo izdano pogojno dovoljenje za promet, bo podjetje, ki ga trži, zagotovilo podatke iz potekajoče študije o učinkovitosti in varnosti zdravila pri zdravljenju ploščatoceličnega karcinoma kože.
It is used in patients who cannot have surgery or treatment with radiation to cure their disease. 
Uporablja se pri bolnikih, pri katerih ne more biti opravljen kurativni kirurški poseg ali kurativno obsevanje.
What are the risks associated with Libtayo? 
Kakšna tveganja so povezana z zdravilom Libtayo?
Libtayo is effective at treating cutaneous squamous cell carcinoma in many patients. 
Zdravilo Libtayo je učinkovito pri zdravljenju ploščatoceličnega karcinoma kože pri številnih bolnikih.
Cancer cells can make proteins (PD-L1 and PD-L2) that attach to this receptor and switch off the activity of the T cells, preventing them from attacking the cancer. 
Rakave celice lahko tvorijo beljakovine (PD-L1 in PD-L2), ki se vežejo na ta receptor in onemogočijo delovanje celic T, tako da te ne morejo napasti rakavih celic.
What information is still awaited for Libtayo? 
Katere informacije o zdravilu Libtayo še pričakujemo?
For the full list of side effects and restrictions with Libtayo, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Libtayo glejte navodilo za uporabo.
The active substance in Libtayo, cemiplimab, is a monoclonal antibody, a type of protein that has been designed to recognise and attach to a receptor (target) called PD-1 found on certain cells of the immune system called T cells. 
Učinkovina v zdravilu Libtayo, cemiplimab, je monoklonsko protitelo, tj. vrsta beljakovine, ki je bila zasnovana tako, da prepozna receptor (prijemališče), imenovano PD-1, ki se nahaja na določenih celicah imunskega sistema, imenovanih celice T, in se veže nanj.
By attaching to the receptor, cemiplimab prevents PD-L1 and PD-L2 from switching off the T cells, thereby increasing the ability of the immune system to kill cancer cells. 
Cemiplimab z vezavo na receptor prepreči, da bi beljakovini PD-L1 in PD-L2 onemogočili delovanje celic T, s čimer se poveča sposobnost imunskega sistema za uničevanje rakavih celic.
Libtayo is effective at treating cutaneous squamous cell carcinoma, a cancer with few treatment options once it has spread. 
Zdravilo Libtayo je učinkovito pri zdravljenju ploščatoceličnega karcinoma kože, tj. rakavega obolenja, za katerega obstaja le malo možnosti zdravljenja, potem ko se ta enkrat razširi.
How does Libtayo work? 
Kako zdravilo Libtayo deluje?
Libtayo contains the active substance cemiplimab. 
Zdravilo Libtayo vsebuje učinkovino cemiplimab.
How is Libtayo used? 
Kako se zdravilo Libtayo uporablja?
In the MRP Sweden is the Reference Member State (RMS) and Austria, Belgium, Denmark, Finland, France, Greece, Germany, Italy, Ireland, Luxembourg, The Netherlands, Portugal, Spain and the United Kingdom are Concerned Member States (CMS). 
V postopku medsebojnega priznavanja je bila Švedska referenčna država članica, medtem ko so bile Avstrija, Belgija, Danska, Finska, Francija, Grčija, Nemčija, Italija, Irska, Luksemburg, Nizozemska, Portugalska, Španija in Združeno kraljestvo zadevne države članice.
SERETIDE DISKUS and associated names (See Annex I) 
SERETIDE DISKUS in z njim povezana imena (glejte Dodatek I)
PERSUANT TO ARTICLE 6(13) OF COMMISSSION REGULATION (EC) No 1084/2003 FOR 
PREDLOŽENO V SKLADU S ČLENOM 6(13) UREDBE KOMISIJE (ES) št. 1084/2003,
In several EU Member States Seretide Diskus and associated names are approved through the Mutual Recognition Procedure (MRP). 
V številnih državah članicah EU je bilo zdravilo Seretide Diskus in z njim povezana imena odobreno s postopkom medsebojnega priznavanja (MRP).
Seretide Diskus and associated names (see Annex I) contain salmeterol and fluticasone propionate, a fixed dose combination of the long acting β-agonist salmeterol and the inhaled corticosteroid fluticasone propionate and is indicated for the regular treatment of asthma where use of a combination product (long-acting beta-2-agonist and inhaled corticosteroid) is appropriate: - patients not adequately controlled with inhaled corticosteroids and ‘as needed' inhaled short acting beta-2-agonist or - patients already adequately controlled on both inhaled corticosteroid and long-acting beta-2-agonist. 
Zdravilo Sertide Diskus in z njim povezana imena (glejte Dodatek I), ki vsebuje salmeterol in flutikazon propionat, kombinacijo fiksnih odmerkov dolgo delujočega β-agonista (LABA) salmeterola in inhalacijskega kortikosteroida (ICS) flutikazon propionata (FP), je indicirano za običajno zdravljenje astme, kadar je uporaba kombiniranega zdravila (dolgo delujočega β-2-agonista in inhalacijskega kortikosteroida) ustrezna: pri bolnikih, pri katerih z inhalacijskimi kortikosteroidi in »po potrebi« z inhalacijskim kratko delujočim beta-2-agonistom ni mogoče doseči zadostnega nadzora bolezni, ali pri bolnikih, pri katerih je bilo mogoče že z inhalacijskimi kortikosteroidi in dolgo delujočim beta-2-agonistom vzpostaviti zadosten nadzor bolezni.
This summary was last updated on 12/04/2011. 
Povzetek je bil nazadnje posodobljen dne 12/04/2011.
Wash hands after using these products. 
Po uporabi zdravila si umijte roke.
The European Commission granted a marketing authorisation valid throughout the European Union, for Veraflox to Bayer Animal Health GmbH on 12/04/2011. 
Evropska komisija je dovoljenje za promet z zdravilom Veraflox, veljavno po vsej Evropski uniji, odobrila družbi Bayer Animal Health GmbH dne 12/04/2011.
In case of contact, rinse immediately with plenty of water. 
V primeru stika predel takoj izperite z veliko količino vode.
The dose and duration of treatment depend on the species of the animal being treated and its body weight, the nature and severity of the infection, and the animal's response to the treatment. 
Odmerek in trajanje zdravljenja sta odvisna od živalske vrste, njene telesne mase, narave in resnosti okužbe ter odziva živali na zdravljenje.
Other information about Veraflox: 
Druge informacije o zdravilu Veraflox:
Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP), on the basis of the documentation provided, led to the recommendations on the conditions of use. 
Njegov namen je pojasniti, kako je Odbor za zdravila za uporabo v veterinarski medicini (CVMP) ocenil predloženo dokumentacijo, na podlagi katere je oblikoval priporočila glede uporabe zdravila.
Pradofloxacin 
Veraflox pradofloksacin
The studies showed that Veraflox was at least as effective as the comparator medicines in all indications. 
Študije so pokazale, da je zdravilo Veraflox pri vseh indikacijah vsaj tako učinkovito kot primerjalna zdravila.
Veraflox 15 mg tablets can be used in both cats and dogs. 
Zdravilo Veraflox 15 mg tablete se uporablja pri mačkah in psih.
It is available as brownish tablets containing 15 mg, 60 mg or 120 mg pradofloxacin, and as a yellowish/beige coloured oral suspension, containing 25 mg/ml pradofloxacin. 
Na voljo je v obliki rjavkastih tablet, ki vsebujejo 15 mg, 60 mg ali 120 mg pradofloksacina, ter peroralne suspenzije rumenkaste do bež barve, ki vsebuje 25 mg/ml pradofloksacina.
It can also be used in conjunction with dental treatment in dogs with severe gum infections. 
Uporablja se lahko tudi pri zdravljenju zob pri psih s hudimi okužbami dlesni.
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Veraflox exceed the risks for the treatment of certain specified infections in dogs and cats and recommended that Veraflox be given a marketing authorisation. 
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je zaključil, da so koristi zdravila Veraflox pri zdravljenju določenih navedenih okužb pri psih in mačkah večje od tveganj in priporočil, da se zanj odobri dovoljenje za promet.
Veraflox must not be used in young growing dogs, in kittens below 6 weeks of age, in animals with joint problems caused by damage to the cartilage, or in animals with central nervous system disorders such as epilepsy. 
Zdravila Veraflox se ne sme uporabljati za rastoče pse, mucke do 6 tednov starosti, za živali s težavami s sklepi zaradi poškodbe hrustanca ali za živali z boleznimi centralnega živčnega sistema, kot je epilepsija.
Veraflox is a medicine that contains pradofloxacin. 
Veraflox je zdravilo, ki vsebuje zdravilno učinkovino pradofloksacin.
What benefit has Veraflox shown during the studies? 
Kakšne koristi je zdravilo Veraflox izkazalo med študijami?